title: Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase.
abstract: Crotty et al. recently proposed the primary antiviral action of ribavirin to be that of a potent RNA mutagen [Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., and Cameron, C. E. (2000) Nat. Med. 6, 1375-1379]. Here we investigate the effect of ribavirin triphosphate (RTP) on RNA synthesis catalyzed by a full-length hepatitis C virus (HCV) RNA polymerase in vitro. HCV polymerase can use RTP as a nucleotide substrate in a template-dependent manner, incorporating it opposite a pyrimidine (C or U) template residue, but not a purine (A or G). Kinetic analysis revealed that incorporation of ribavirin monophosphate (RMP) across from C is 3 times more efficient catalytically than that across from U, as determined by the k(cat)/K(m) parameter. The efficiency of RMP incorporation, however, is 50-100 fold lower than that of the natural NMP. RMP incorporation does not lead to termination of RNA chain synthesis, as evidenced by the ability of the polymerase to extend its RNA product many nucleotides beyond the site of RMP incorporation. However, multiple-RMP incorporation at low GTP concentrations induced the formation of stalled elongation complexes, particularly at the template region containing consecutive C residues. Most, but not all, such elongation blocks can be relieved by the re-addition of GTP. When ribavirin is present in the RNA template, pyrimidine (but neither purine nor ribavirin) monophosphate is incorporated opposite ribavirin, but at an exceedingly low catalytic efficiency (200-3000-fold lower) compared to the efficiencies of those templated by A or G. Consequently, the level of RNA synthesis on a ribavirin-containing template is significantly reduced. These findings suggest that ribavirin not only is mutagenic but also interferes with HCV polymerase-mediated RNA synthesis.
authors.affiliation: Department of Molecular Microbiology and Immunology, University of Southern California School of Medicine, Los Angeles, California 90033-1054, USA.
authors.forename: Nam V
authors.initials: NV
authors.lastname: Vo
authors.forename: Kung-Chia
authors.initials: KC
authors.lastname: Young
authors.forename: Michael M C
authors.initials: MM
authors.lastname: Lai
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism*; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism*; D016679:Genome, Viral; D006160:Guanosine Triphosphate / Q000378:metabolism; D016174:Hepacivirus / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D009154:Mutation; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D012254:Ribavirin / Q000737:chemistry / Q000378:metabolism*; D014158:Transcription, Genetic; D014764:Viral Proteins / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D011687:Purines; D011743:Pyrimidines; D014764:Viral Proteins; D012254:Ribavirin; D012313:RNA; D006160:Guanosine Triphosphate; D012321:DNA-Directed RNA Polymerases